두경부암 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)
Head and Neck Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
상품코드:1420934
리서치사:Transparency Market Research
발행일:2023년 12월
페이지 정보:영문 178 Pages
라이선스 & 가격 (부가세 별도)
한글목차
두경부암 시장 - 보고서 범위
세계의 두경부암 시장에 관한 TMR의 보고서는 과거와 현재의 성장 동향 및 2023년부터 2031년까지의 예측기간 동안 시장 지표의 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 2023년을 기준 연도, 2031년을 예측 연도로 삼아 2017년부터 2031년까지의 세계 시장 매출을 제공합니다. 또한 2023년부터 2031년까지 연평균 성장률(CAGR %)도 제공합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 이루어지고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 메이커와의 인터뷰를 실시했습니다. 2차 조사에는 두경부암 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차 보고서, 프레스 릴리스 및 관련 문서에 대한 참조가 포함됩니다.
시장 현황
2023년 시장 가치
16억 달러
2031년 시장 가치
29억 달러
CAGR
6.8%
이 보고서는 세계의 두경부암 시장 경쟁 상황을 자세히 살펴봅니다. 세계의 두경부암 시장에서 활동하는 주요 기업이 확인되었으며, 각각의 기업이 다양한 속성의 관점에서 프로파일링됩니다. 기업 개요, 재무 상황, 최근의 동향, SWOT는 이 보고서에서 소개되고 있는 세계의 두경부암 시장 기업의 속성입니다.
목차
제1장 주요 요약
제2장 가정과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
시장 세분화
개요
시장 역학
세계 시장 분석과 예측, 2017-2031년
제5장 중요한 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 인수합병
COVID-19 감염증 팬데믹이 업계에 미치는 영향
제6장 세계 시장 분석과 예측 : 약제 클래스별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 약제 클래스별, 2017-2031
EGFR 억제제
유사분열 억제제
항PD-1 단클론항체
기타
시장 매력도 : 약제 클래스별
제7장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 유통 채널별, 2017-2031
병원 약국
소매 약국
E-Commerce
시장 매력 : 유통 채널별
제8장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별, 2017-2031
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력 : 지역별
제9장 북미 시장 분석과 예측
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 상황
시장 기업 - 경쟁 매트릭스(기업 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
Sanofi
Pfizer
Eli Lilly and Company
F. Hoffman-La Roche
AstraZeneca
Merck KgaA
Bayer AG
Bristol-Myers Squibb Company
Galera
Fresenius Kabi
Teva Pharmaceuticals
KSM
영문 목차
영문목차
Head and Neck Cancer Market - Scope of Report
TMR's report on the global head and neck cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global head and neck cancer market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global head and neck cancer market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the head and neck cancer market.
Market Snapshot
Market Value in 2023
US$ 1.6 Bn
Market Value in 2031
US$ 2.9 Bn
CAGR
6.8%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global head and neck cancer market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global head and neck cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global head and neck cancer market.
The report delves into the competitive landscape of the global head and neck cancer market. Key players operating in the global head and neck cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global head and neck cancer market profiled in this report.
Key Questions Answered in Global head and neck cancer Market Report:
What is the sales/revenue generated by head and neck cancer across all regions during the forecast period?
What are the opportunities in the global head and neck cancer market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Head and Neck Cancer Market - Research Objectives and Research Approach
The comprehensive report on the global head and neck cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global head and neck cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global head and neck cancer market.
Table of Contents
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Head and Neck Cancer Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. EGFR Inhibitors
6.3.2. Mitotic Inhibitors
6.3.3. Anti-PD-1 Monoclonal Antibodies
6.3.4. Others
6.4. Market Attractiveness, by Drug Class
7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017-2031
7.3.1. Hospitals Pharmacies
7.3.2. Retail Pharmacies
7.3.3. E-commerce
7.4. Market Attractiveness, by Distribution Channel
8. Global Head and Neck Cancer Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Head and Neck Cancer Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017-2031
9.2.1. EGFR Inhibitors
9.2.2. Mitotic Inhibitors
9.2.3. Anti-PD-1 Monoclonal Antibodies
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospitals Pharmacies
9.3.2. Retail Pharmacies
9.3.3. E-commerce
9.4. Market Value Forecast, by Country, 2017-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Head and Neck Cancer Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. EGFR Inhibitors
10.2.2. Mitotic Inhibitors
10.2.3. Anti-PD-1 Monoclonal Antibodies
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Hospitals Pharmacies
10.3.2. Retail Pharmacies
10.3.3. E-commerce
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. EGFR Inhibitors
11.2.2. Mitotic Inhibitors
11.2.3. Anti-PD-1 Monoclonal Antibodies
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospitals Pharmacies
11.3.2. Retail Pharmacies
11.3.3. E-commerce
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Head and Neck Cancer Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. EGFR Inhibitors
12.2.2. Mitotic Inhibitors
12.2.3. Anti-PD-1 Monoclonal Antibodies
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017-2031
12.3.1. Hospitals Pharmacies
12.3.2. Retail Pharmacies
12.3.3. E-commerce
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. EGFR Inhibitors
13.2.2. Mitotic Inhibitors
13.2.3. Anti-PD-1 Monoclonal Antibodies
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017-2031
13.3.1. Hospitals Pharmacies
13.3.2. Retail Pharmacies
13.3.3. E-commerce
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Sanofi
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Eli Lilly and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. F. Hoffman-La Roche
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. AstraZeneca
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Merck KgaA
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Bayer AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Bristol-Myers Squibb Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Galera
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Fresenius Kabi
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Teva Pharmaceuticals
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
